Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 17Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasm Metastasis 6Prostatic Neoplasms 5Melanoma 5Lung Neoplasms 5Solid Tumor 3Pain, Postoperative 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Anxiety Disorders 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Pain 2Glioma 2Colonic Neoplasms 2Choledocholithiasis 2Choledochal Cyst 2Carcinoma 2Advanced Solid Tumor 2Advanced Malignancies 2cMET-dysregulated Advanced Solid Tumors 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

pexidartinib 3nilotinib 2emactuzumab 1cabiralizumab 1Tolbutamide 1Midazolam 1Bro protein, Drosophila 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Synovitis, Pigmented Villonodular × Midazolam × Clear all
NCT03291288 2021-05-14

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Daiichi Sankyo

Phase 1 Completed
32 enrolled 22 charts

Synovitis, Pigmented Villonodular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡